Earnings Preview: Eli Lilly - Analyst Blog
July 14 2011 - 8:38AM
Zacks
Eli Lilly &
Company (LLY) is all set to announce its second quarter
2011 results on July 21, 2011 before the opening bell. The Zacks
Consensus Estimate for the second quarter is $1.17, representing a
year-over-year decrease of 5.6%.
Eli Lilly has surpassed earnings
estimates consistently in the last four quarters with a trailing
average of 5.96%.
First Quarter 2011 Recap
Eli Lilly reported first quarter
earnings per share of $1.24, seven cents more than the Zacks
Consensus Estimate and 5% above last year's $1.18. First quarter
results were driven by higher revenues and a lower tax rate.
First quarter revenues increased 6%
to $5.8 billion, slightly above the Zacks Consensus Estimate of
$5.7 billion. Revenues were helped by strong performances in
international markets.
Reported earnings, however,
declined 16% to $0.95, including the impact of restructuring
charges and costs associated with the company’s agreement with
Boehringer Ingelheim.
(Read our full coverage of the first quarter 2011 earnings
report at Eli Lilly Tops, Maintains Outlook ) .
Agreement of
Analysts
Estimate revisions for Eli Lilly
have been scarce for the past month. In that time, only 1 of the 14
analysts covering Eli Lilly for the second quarter of 2011 has
revised his/her earnings estimate. The analyst moved lower..
Estimates for 2011 have been
revised by only 2 analysts over the last 30 days. There has been a
movement in both directions. We expect the top-and bottom-lines to
remain under pressure from late 2011 as the contraction in lead
product Zyprexa’s (a treatment for schizophrenia and bipolar
disorder) sales more than offsets growth in Cymbalta (approved for
treating depression), the diabetes franchise and sales of new
products.
Magnitude of Estimate
Revisions
Estimates for the second quarter of
2011 have remained static at $1.17 over the last 30 days due to the
lack of significant estimate revisions by analysts following the
stock. Estimates for 2011 have gone up by only a penny to $4.28
over a similar time period due to the lack of significant estimate
revisions.
Neutral on Eli
Lilly
We currently have a Neutral
recommendation on Eli Lilly. The stock carries a Zacks #3 Rank
(Hold rating) in the short run.
Even though we are concerned about
the generic threat to key products and the lack of a significant
enough pipeline to offset key patent expirations at Eli Lilly, a
strong performance of the diabetes business should offer some
downside support.
The primary pipeline candidate at
Eli Lilly’s diabetes pipeline is Bydureon. Eli
Lilly has co-developed the candidate with Alkermes,
Inc. (ALKS) and Amylin Pharmaceuticals, Inc.
(AMLN). Bydureon is approved in the
European Union and a response to the US Food and Drug
Administration’s complete response letter is slated for the third
quarter of 2011.
The other diabetes candidates at
Eli Lilly include empagliflozin (potential to launch in 2014),
dulaglutide (regulatory submission potentially in 2013) and basal
insulins (phase III studies scheduled to commence in the second
half of 2011).
The ramp of blood thinner Effient,
upside from the ImClone deal and Eli Lilly’s focus on emerging
markets should provide a boost to revenues. We are also pleased to
see Lilly pursuing small acquisitions and in-licensing deals to
boost its pipeline.
ALKERMES INC (ALKS): Free Stock Analysis Report
AMYLIN PHARMA (AMLN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
Zacks Investment Research
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2024 to Jun 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2023 to Jun 2024